Publication | Closed Access

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Survival OutcomesBreast OncologyMedicinePathologyPathological Complete ResponseBreast CancerCancer TreatmentOncologyRadiation OncologyPhase 3